Know which assets
to back before the
budget is spent
Portfolio optimization from Thelansis weighs every asset on clinical, commercial, regulatory, and competitive evidence, so you invest where value is highest and risk is understood.
- Prioritize with evidence, not intuition
- Reduce development risk across programs
- Align science and commercial teams on one plan
Without a
structured view,
portfolios drift
Limited resources, competing priorities, and market uncertainty make every portfolio call harder. These are the symptoms we see most.
Low-value or overcrowded indication bets
Resources stretched across too many programs
Slow decisions made without enough evidence
Missed opportunities in emerging markets
Science and commercial teams pulling in different directions
Rising costs and an inefficient portfolio
What changes when your portfolio is optimized
Limited resources, competing priorities, and market uncertainty don’t go away. How you decide does.
Without structured optimization
- Bets on low-value or overcrowded indications
- Resources stretched across too many programs
- Slow decisions with too little evidence
- Emerging-market opportunities missed
- Science and commercial teams misaligned
- Rising costs and an inefficient portfolio
With Thelansis
- Investment focused on high-value, less crowded indications
- Budget concentrated where value is highest
- Faster decisions backed by evidence
- White space identified early
- One set of priorities everyone agrees on
- Better portfolio ROI and long-term growth
One portfolio, six lenses
Our 360° evaluation framework replaces intuition with structured evidence, quantifying both the opportunity and the uncertainty behind every asset.
Competitive landscape
Rival assets, their positioning, and how competitor moves affect your plans.
How an engagement works
Align on goals
Agree on strategic priorities, scoring criteria, and the assets in scope.
Gather the evidence
Assess every asset through all six lenses.
Score and prioritize
Rank assets on risk-adjusted value and map them on the matrix.
Decide and act
Work through the recommendations together and leave with an investment roadmap.
How healthy is your portfolio?
Limited resources, competing priorities, and market uncertainty make every portfolio call harder. These are the symptoms we see most.
- Your portfolio health score
- Your biggest gaps, ranked
- How to close each one
Nine ways we support your portfolio
Portfolio strategy development
Set the direction and balance of your pipeline.
Asset prioritization and scoring
Rank assets against consistent, transparent criteria.
Competitive intelligence assessments
Track rival programs and how they change your odds.
Epidemiology and market analysis
Size patient populations and market potential.
Regulatory pathway analysis
Map approval routes, precedents, and timelines.
Market access assessments
Gauge payer expectations and reimbursement hurdles.
White-space identification
Find underserved indications and markets.
Risk-adjusted portfolio reviews
Weigh value against the probability of success.
Executive decision support
Turn analysis into clear choices for leadership.
Find out where your
portfolio stands
Start with a free review call, or take the six-question health check first.
The questions on your
leadership team's agenda
Each one maps to a service that answers it with evidence.
Which indications should we pursue first?
Where should we invest, partner, or diversify?
Which assets need repositioning or deprioritization?
Which markets offer the greatest long-term opportunity?
How will competitor activity affect our strategy?
What portfolio risks need immediate attention?
Explore related consulting
Therapy Area Strategy
Indication and Asset Prioritization
Target Product Profile Analysis
Market Forecasting
Talk to Our Experts
Share your portfolio goals and get strategies tailored to your needs.
- A reply within one business day
- Confidential from the first conversation
- No obligation
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
